Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct:59:79-86.
doi: 10.1016/j.breast.2021.06.003. Epub 2021 Jun 11.

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study

Ariane Mamguem Kamga  1 , Oumar Billa  2 , Sylvain Ladoire  3 , Marie-Laure Poillot  2 , Geneviève Jolimoy  4 , Patrick Roignot  5 , Charles Coutant  6 , Isabelle Desmoulins  3 , Marc Maynadie  7 , Tienhan Sandrine Dabakuyo-Yonli  8
Affiliations

Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study

Ariane Mamguem Kamga et al. Breast. 2021 Oct.

Abstract

Purpose: To identify prognostic factors of invasive-disease free survival (iDFS) in women with non-metastatic hormone receptor positive (HR+) breast cancer (BC) in daily routine practice.

Methods: We performed a retrospective study using data from the Côte d'Or breast and gynecological cancer registry in France. All women diagnosed with primary invasive non-metastatic HR + BC from 1998 to 2015 and treated by endocrine therapy (ET) were included. Women with bilateral tumors or who received ET for either metastasis or relapse were excluded. We performed adjusted survival analysis and Cox regression to identify prognostic factors of iDFS.

Results: A total of 3976 women were included. Age at diagnosis, ET class, SBR grade, treatment, stage and comorbidity were independently associated with iDFS. Women who had neither surgery nor radiotherapy had the highest risk of recurrence (HR = 3.75, 95%CI [2.65-5.32], p < 0.0001). Receiving aromatase inhibitors (AI) was associated with a lower risk of recurrence (HR = 0.70, 95%CI [0.54-0.90], p = 0.055) compared to tamoxifen. Compared to women with no comorbidities, women with 1 or 2 comorbidities were more likely to receive AI (OR = 1.63, 95%CI [1.22-2.17], p = 0.0009).

Conclusions: Comorbidities, age at diagnosis and previous treatment were associated with iDFS in non-metastatic HR + BC patients. This study also showed that women who received tamoxifen for their cancer experienced worse iDFS compared to women treated with AI.

Keywords: Breast cancer; Endocrine therapy; Hormone receptor positive; Invasive disease-free survival; Non-metastatic cancer.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

Figures

Fig. 1
Fig. 1
Flow chart.
Fig. 2
Fig. 2
Age-adjusted survival curves according to ET class.
Fig. 3
Fig. 3
Trends in ET prescription according to class and type over time.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. Aug 27. - PMC - PubMed
    1. Hershman D.L., Shao T., Kushi L.H., Buono D., Tsai W.Y., Fehrenbacher L. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Canc Res Treat. 2011;126(2):529–537. Apr. - PMC - PubMed
    1. Howell A. The “Arimidex”, Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. Rev Recent Clin Trials. 2006;1(3):207–215. Sep. - PubMed
    1. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757. Dec 29. - PubMed
    1. Derks M.G.M., Blok E.J., Seynaeve C., Nortier J.W.R., Kranenbarg E.M.-K., Liefers G.-J. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(9):1211–1220. Sep 1. - PubMed